Drug Profile
Cytomegalovirus glycoprotein vaccine - Sanofi
Latest Information Update: 04 Apr 2022
Price :
$50
*
At a glance
- Originator Chiron
- Developer National Institute of Allergy and Infectious Diseases; sanofi pasteur; University of Alabama at Birmingham
- Class Cytomegalovirus vaccines; Glycopeptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 26 Jul 2015 No recent reports of development identified - Phase-II for Cytomegalovirus infections in USA (IM)
- 15 Sep 2009 Efficacy data from a phase II trial in Cytomegalovirus infections presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
- 18 Mar 2009 Interim efficacy and safety data from a phase II trial in Cytomegalovirus infections released by University of Alabama at Birmingham